ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.19
+0.12 (1.49%)
At close: Apr 23, 2026, 4:00 PM EDT
8.11
-0.08 (-0.98%)
Pre-market: Apr 24, 2026, 5:53 AM EDT
ImmunityBio Employees
As of December 31, 2025, ImmunityBio had 691 total employees, including 684 full-time and 7 part-time employees. The number of employees increased by 11 or 1.62% compared to the previous year.
Employees
691
Change
11
Growth
1.62%
Revenue / Employee
$163,948
Profits / Employee
-$508,535
Market Cap
8.46B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 691 | 11 | 1.62% | 684 | 7 |
| Sep 30, 2025 | 673 | 1 | 0.15% | 673 | 0 |
| Jun 30, 2025 | 685 | 63 | 10.13% | 685 | 0 |
| Mar 31, 2025 | 671 | 43 | 6.85% | 671 | 0 |
| Dec 31, 2024 | 680 | 52 | 8.28% | 680 | 0 |
| Sep 30, 2024 | 672 | 2 | 0.30% | 672 | 0 |
| Jun 30, 2024 | 622 | -61 | -8.93% | 622 | 0 |
| Mar 31, 2024 | 628 | -75 | -10.67% | 628 | 0 |
| Dec 31, 2023 | 628 | -97 | -13.38% | 628 | 0 |
| Sep 30, 2023 | 670 | -90 | -11.84% | 670 | 0 |
| Jun 30, 2023 | 683 | -57 | -7.70% | 683 | 0 |
| Mar 31, 2023 | 703 | 15 | 2.18% | 703 | 0 |
| Dec 31, 2022 | 725 | 138 | 23.51% | 725 | 0 |
| Sep 30, 2022 | 760 | 222 | 41.26% | 760 | 0 |
| Jun 30, 2022 | 740 | 229 | 44.81% | 740 | 0 |
| Mar 31, 2022 | 688 | 213 | 44.84% | 688 | 0 |
| Dec 31, 2021 | 587 | 112 | 23.58% | 587 | 0 |
| Sep 30, 2021 | 538 | 273 | 103.02% | 538 | 0 |
| Jun 30, 2021 | 511 | 246 | 92.83% | 511 | 0 |
| Mar 31, 2021 | 475 | 210 | 79.25% | 475 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 925 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 238 |
IBRX News
- 21 hours ago - IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt - PRNewsWire
- 1 day ago - IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - GlobeNewsWire
- 2 days ago - IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline - Newsfile Corp
- 2 days ago - ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia - Benzinga
- 2 days ago - ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership - Business Wire
- 3 days ago - IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses - GlobeNewsWire
- 3 days ago - ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - GlobeNewsWire
- 7 days ago - IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt - PRNewsWire